Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma

Bone Marrow Transplantation

Volumn 50, Issue 6, 2015, Pages 802-807

  Sahebi, F ^a,b   Iacobelli, S ^c   Biezen, A V ^d   Volin, L ^e   Dreger, P ^f   Michallet, M ^g   Ljungman, P T ^h   De Witte, T ⁱ   Henseler, A ^d   Schaap, N P M ⁱ   Lopez Corral L ^j   Poire, X ^k   Passweg, J ^l   Hamljadi, R M ^m   Thomas, S H ^a   Schonland, S ^f   Gahrton, G ^h   Morris, C ⁿ   Kroger N ^o   Garderet, L ^p  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^k CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^l UNIVERSITY HOSPITAL BASEL   (Switzerland)

^m Centre Pierre et Marie Curie   (Algeria)

ⁿ QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^o UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^p HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER RECURRENCE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; ALLOGRAFT; AUTOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTICENTER STUDY; SURVIVAL RATE;

ADULT; AGED; ALLOGRAFTS; AUTOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84930383252     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.45     Document Type: Article

References (22)

1. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454
2. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755-760
3. Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C, et al. Long-term followup results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008; 112: 3914-3915
4. Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591-3593
5. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110-1120
6. Gahrton G, Iacobelli S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMTNMAM2000 study. Blood 2013; 121: 5055-5063
7. Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011; 12: 1195-1203
8. Lokhorst HM, Van Der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012; 119: 6219-6225
9. Knop S, Liebisch P, Hebart H, Holler E, Engelhardt M, Bargou RC, et al. Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 Myeloma -an interim analysis of the German DSMM V trial. ASH Annu Meeting Abstr 2009; 114: 51
10. Giaccone L, Storer B, Patriarca F, Rotta M, Sorasio R, Allione B, et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011; 117: 6721-6727
11. Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109: 3588-3594
12. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123
13. Sahebi F, Garderet L, Iacobelli S, Biezen AV, Gahrton G, Kroger N, et al. A comparison of two different reduced intensity conditioning (RIC) allograft strategies in patients with multiple myeloma. An EBMT analysis. ASH Annu Meeting Abstr 2010; 116: 3512
14. Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Perez-Simon JA, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010; 28: 4521-4530
15. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005; 105: 4532-4539
16. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633
17. Ringden O, Shrestha S, da Silva GT, Zhang MJ, Dispenzieri A, Remberger M, et al. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant 2012; 47: 831-837
18. El-Cheikh J, Crocchiolo R, Furst S, Stoppa AM, Ladaique P, Faucher C, et al. Long-term outcome after allogeneic stem-cell transplantation with reducedintensity conditioning in patients with multiple myeloma. Am J Hematol 2013; 88: 370-374
19. Danylesko I, Shimoni A, Nagler A. Allogeneic stem cell transplantation and targeted immunotherapy for multiple myeloma. Clin Lymphoma Myeloma Leuk 2013; 13: S330-S348
20. Sahebi F, Shen Y, Thomas SH, Rincon A, Murata-Collins J, Palmer J, et al. Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study. Br J Haematol 2013; 160: 199-206
21. Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009; 113: 3383-3391
22. Vekemans MC, Michaux L, Van Den Neste E, Ferrant A. Long-term survival after allogeneic stem cell transplantation for advanced stage multiple myeloma. Br J Haematol 2014; 166: 616-618